Reset Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Company may now initiate Phase 2b trial for treatment of demoralization syndrome in patients with cancerNEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health conditions related to life-altering diseases, today announces that the Company has received a Safe to Proceed notification from the U.S. Food and Drug Administration (FDA) regarding its Invest

  Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to announce a significant licensing agreement between Filament Health and Reset...

This randomized clinical trial examines the timing of onset of action, durability of benefit, and safety profile of single-dose psilocybin in patients with majo

Fried food consumption was associated with higher risks for anxiety and depression, according to findings published in the Proceedings of the National Academy of Sciences of the United States of America.

EQS-News: Reset Pharmaceuticals, Inc. / Key word(s): Personnel Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer 05.01.2023 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement.  Reset Pharmaceuticals Appoints Innes Meldrum as...